New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For BIIB From The Last 14 Days
Check below for free stories on BIIB the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 23, 2014
14:10 EDTBIIBBiogen discloses receipt of subpoenas from federal, state governments
Subscribe for More Information
13:19 EDTBIIBBiogen shares defended at Deutsche Bank
Subscribe for More Information
11:49 EDTBIIBBiogen price target lowered to $370 from $395 at Piper Jaffray
Subscribe for More Information
07:05 EDTBIIBBiogen reports Q1 Avonex revenue up 2% vs. last year
Reports Q1 Tysabri revenue up 41% to $441M, Tecfidera revenue $506M. Biogen Idec started 2014 on a strong note with the approval of TECFIDERA for MS patients in Europe and ALPROLIX for hemophilia B patients in the United States and Canada,” said CEO George A. Scangos, Ph.D. “Following an excellent first year of sales in the U.S., TECFIDERA is off to a solid start in Germany, with plans to launch in additional countries in the coming months. Through the remainder of 2014 we anticipate regulatory decisions on new products for hemophilia and MS, and several important early-stage proof-of-concept and clinical study read-outs – and through our collaboration with Eisai we are building one of the broadest research portfolios targeting Alzheimer’s disease.”
07:04 EDTBIIBBiogen sees FY14 EPS ex-items $11.35-$11.45, consensus $11.32
Sees FY14 revenue growth 26%-28%, consensus $8.63B.
07:03 EDTBIIBBiogen reports Q1 EPS $2.47, consensus $2.56
Subscribe for More Information
06:54 EDTBIIBCambridge Healthtech Institute to hold a conference
Subscribe for More Information
April 22, 2014
15:32 EDTBIIBNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Procter & Gamble (PG), consensus $1.02; Boeing (BA), consensus $1.56; Biogen Idec (BIIB), consensus $2.56; Dow Chemical (DOW), consensus 71c; EMC Corporation (EMC), consensus 35c; Thermo Fisher (TMO), consensus $1.40; Praxair (PX), consensus $1.51; General Dynamics (GD), consensus $1.64; Johnson Controls (JCI), consensus 65c; Norfolk Southern (NSC), consensus $1.15; Reynolds American (RAI), consensus 74c; Delta Air Lines (DAL), consensus 29c; Northrop Grumman (NOC), consensus $2.15; Air Products & Chemicals (APD), consensus $1.35; TD Ameritrade (AMTD), consensus 34c; Ingersoll-Rand (IR), consensus 26c; Dr Pepper Snapple (DPS), consensus 59c; Polaris Industries (PII), consensus $1.16; Ryder System (R), consensus 87c.
April 21, 2014
08:16 EDTBIIBBiogen signs Factor VIII license agreement with Amunix
Subscribe for More Information
April 20, 2014
16:45 EDTBIIBBiogen hemophilia drug Alprolix priced similar to older treatments, Reuters says
Subscribe for More Information
April 16, 2014
08:34 EDTBIIBPiper Jaffray tech and biopharma analysts hold analyst/industry conference call
Technical Analyst Johnson, along with BioPharma Analysts, discuss the recent downturn in the biotech and specialty pharmaceuticals industries on an Analyst/Industry conference call to be held on April 17 at 10 am.
April 14, 2014
09:46 EDTBIIBBiogen hugs support at critical technical juncture, levels to watch
Subscribe for More Information
07:33 EDTBIIBBiogen to present Plegridy, Tecfidera data at AAN annual meeting
Subscribe for More Information
April 11, 2014
10:15 EDTBIIBBiogen heads for test of $280 area
The shares are heading lower after an early bounce attempt and are now just above the session low at $280.13. As noted yesterday, a break below $280 would confirm topping in the shares. Support below $280 is at $273.45. Resistance is at $285.
April 10, 2014
15:13 EDTBIIBBiogen tumbles, nearing important test of support
Subscribe for More Information
09:00 EDTBIIBBiogen May volatility elevated at 43 into Q1 and revenue outlook
Subscribe for More Information
07:31 EDTBIIBBiogen names Adam Koppel as SVP, Chief Strategy Officer
Subscribe for More Information
07:08 EDTBIIBBiogen announces positive top-line efficacy, safety results from Phase 3 trial
Biogen Idec and Swedish Orphan Biovitrum AB released positive top-line results of the Kids A-LONG Phase 3 clinical study that evaluated the safety and efficacy of Eloctate, an investigational recombinant factor VIII Fc fusion protein product candidate, in children with severe haemophilia A. Eloctate was generally well-tolerated and no inhibitors were detected. Efficacy analyses showed twice-weekly prophylactic dosing with Eloctate maintained low bleeding rates in children.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use